Belgium-based Aelin Therapeutics has received €27 million in Series A financing from a syndicate of investors to develop a new class of antibiotics against human targets that thus far have been undruggable. The company is a spin-out of the VIB research institute.
OSE Immunotherapeutics SA is set to resume recruitment into a Phase 3 trial of patients with non-small cell lung cancer (NSCLC) following a pause in June to enable investigators to have more time to assess the effect of the treatment which is a neoantigen therapy called Tedopi.
The French specialist pharma company Advicenne Pharma SA raised €27 million in an initial public offering (IPO) of its shares on the Paris Euronext exchange on 4 December to advance its pipeline of drugs for orphan renal and neurological diseases.
Medigene has raised its revenue forecast for 2017 following an agreement to sell its product for the treatment of genital wards, Veregen, to a subsidiary of Novartis. The sale finishes the disposal of its legacy products, enabling the company to focus on immunotherapy.
GW Pharmaceutical Plc, which is developing cannabinoid medicines for epilepsy and other diseases of the central nervous system, reported a 20.1% decline in revenue to £8.2 million for the fiscal year ended 30 September 2017, while its operating loss soared by more than 70% to £153.3 million.
Semma Therapeutics Inc, a company founded by the Harvard University Professor Douglas Melton, has raised $114 million in an oversubscribed Series B financing round to bring a stem cell therapy for Type1 diabetes into the clinic.
MorphoSys AG has increased its financial guidance for 2017 in the wake of a licensing deal with I-Mab Biopharma, a biologics company based in Shanghai, China. The agreement gives I-Mab the right to develop the German company’s antibody for multiple myeloma for the Chinese market.
Siemens AG plans to list its healthcare imaging and diagnostics business, Siemens Healthineers, on the Frankfurt Stock Exchange during the first half of 2018, Europe’s largest industrial manufacturing company said on 29 November.
AstraZeneca Plc has entered into a partnership with the Chinese-government backed Future Industry Investment Fund (FIIF) to create a stand-alone, joint venture company called Dizal Pharmaceutical that will develop and commercialise new medicines in China.
Avelumab, a checkpoint antibody that is the mainstay of Merck KGaA’s immuno-oncology portfolio, has failed to show superior overall survival in patients with metastatic gastric cancer compared with chemotherapy. The data is from a Phase 3 trial called Javelin Gastric 300.